Introduction
There is evidence, both experimental and clinical, that bone marrow-derived cells play an important role in the vascularization of tumors. The extent to which these cells contribute to the endothelial, pericytic and proangiogenic non-structural cells of the tumor vasculature is a matter of debate. As most tumors depend on building new vessels for growth, tumor vessel formation may provide a common therapeutic target shared by different tumor entities. Therefore, efforts have been made to exploit the innate tumor tropism of bone marrowderived cells, including circulating endothelial progenitor cells, to deliver therapeutic payloads specifically to tumor sites. Initial studies transplanted genetically modified bone marrow-derived cells into irradiated mice, followed by post-transplant tumor challenges. 5, 7, 23 These pioneering studies proved the principle that genetically engineered cells can home from the bone marrow to the tumor, where they elicit an anti-tumor response. Similarly, modified CD34 + cells homed to sites of neovascularization in primates and elicited a bystander effect in vitro. 24 However, future clinical application of bone marrow-derived cells for cancer therapy will most likely consist of systemic injection of ex vivo expanded and modified cells, including endothelial progenitors, without bone marrow transplantation. Thus, emerging data showing that expanded or modified mouse and, more important, human EPCs home to experimental tumors, including brain tumors, are encouraging. 2, 17, [25] [26] [27] [28] We investigated the parameters determining the efficacy of human adult blood outgrowth endothelial cells (BOECs) for systemic cancer gene therapy in mice. These cells are attractive candidate cellular vehicles since they can be readily procured from autologous donors and are easily expanded and genetically modified ex vivo. 29, 30 Homing of EPCs to tumors may constitute a major parameter determining their therapeutic efficacy. However, little is known about tumor homing of both endogenous and ex vivo expanded EPCs. VEGFoverexpressed in many tumors -which acts on VEGFR2 expressed by tumor endothelial cells and also on VEGFR1, has been established as a pivotal angiogenic mechanism in tumors. 31, 32 VEGF administration into mice and VEGF secreted by patients with vascular trauma mobilizes endogenous EPCs from the bone marrow. 1, 33 VEGF-triggered mobilization of EPCs from the bone marrow is mediated by matrix metalloproteinase-9 induced in bone marrow cells, possibly via releasing soluble Kit-ligand. 34 VEGF may also attract EPCs to tumors since endogenous and early outgrowth EPCs migrate towards VEGF in vitro. 1, 23 Placental growth factor (PlGF) acting on VEGFR1 is emerging as an enhancer of tumor angiogenesis. VEGFR1 is expressed by endothelial cells, monocytes/ macrophages, neutrophils and their precursors. 35 A common feature of VEGFR1 expressing cells is homing to normal and diseased tissue. Thus, chemotaxis of monocytes is mediated by VEGFR1 in response to both PlGF and VEGF. 36 Furthermore, following transplantation of wild type bone marrow cells into Id1 +/À Id3 À/À mice deficient in tumor angiogenesis, growth and angiogenesis of tumors was restored and VEGFR1 + EPCs were found within the tumor vessels, a process abrogated by blocking VEGFR1. 6 Tumor angiogenesis was impaired in PlGF À/À mice and could be restored by expression of PlGF. 37 PlGF overexpressed in Lewis lung carcinoma cells enhanced tumor growth and angiogenesis. 38 PlGF is also known to increase survival of tumor endothelial cells. 39 Many tumors, including brain tumors, overexpress PlGF associated with increased tumor angiogenesis. [40] [41] [42] [43] [44] [45] [46] [47] [48] Taken together, while these studies implicate PlGF in tumor angiogenesis, its role in recruiting EPCs and BOECs is unknown.
In this paper, we elucidate important parameters determining the efficacy of experimental BOECmediated cancer gene therapy.
Results

Growth and phenotype of BOECs
We compared growth and phenotype of BOECs in a total of 42 cultures derived from PBMCs of 16 healthy donors. In all cultures cells outgrew after 15-20 days, proliferated rapidly and could be passaged for up to 25 times. BOECs expressed VEGFR2, VEGFR1, vWF, CD31,VE-cadherin, a v b 3 , a v b 5 and CD105. They did not or only marginally express CD133, c-kit, CD45, CXCR4, ESL (E-selectin ligand), CD162, CLA, CD49d, CD11a and CD11b (Supplementary Table 1 ). CD34 expression varied (Supplementary Figure 1) and decreased with culture time. BOECs took up acetylated LDL and built vessellike structures on Matrigel (data not shown).
Taken together, these data confirm that BOECs have a mature endothelial phenotype and furthermore show that they express few progenitor-and homing-associated markers.
BOECs target lung metastases and brain tumors
Disseminated metastases cannot be effectively treated by intratumoral injections. We therefore investigated, whether systemically administered BOECs home efficiently to disseminated metastases. An early time point after BOEC injection was chosen for analysis of homing to coincide with the time point at which the prodrug was administered. Tail vein injected DiI-labeled BOECs were found in large numbers in the margins and, to a lesser degree, in the center of lung metastases, but rarely homed to liver or kidney metastases ( Figure 1a and b and data not shown). In contrast, i.v. injected human DiIlabeled fibroblasts did not home to metastases, but were sequestered in the lung (Figure 1c) . Assessment of homing in irradiated mice showed that 76% of the 97 lung metastases examined recruited BOECs (Figure 1d ). While 17 and 18% of the metastases showed strong (Figure 1a ) or marked (Figure 1e and f) BOEC recruitment, respectively, the majority of recruiting metastases showed moderate recruitment. Recruitment did not depend on the size or localization of the lung metastases. Staining of the tumor vessels showed that the margins of the metastases, areas that heavily recruited BOECs (Figure 1a and e), were especially well vascularized (Figure 1e ). Of note, a minority of BOECs was found to be associated with tumor vessels while the majority was found extravascularly (Figure 1e and f) .
We also wanted to know, whether i.v. injected BOECs target orthotopically implanted human brain tumors. BOECs were labeled with BrdU, since the autofluorescence of brain tumors precluded the efficient use of DiIlabeled BOECs. Following systemic administration of BrdU-labeled BOECs numerous BOECs were seen in U87 gliomas, few BOECs were found in LNT-229 and SF126 glioma, and no BOECs were detected in normal brain tissue (Supplementary Figure 2) .
Taken together, after intravenous injection BOECs target the extravascular region of most but not all LLC lung metastases with moderate efficacy. Kidney or liver metastases are not targeted efficiently and brain tumors are targeted differentially.
BOECs are sequestered only transiently and at low density in lung and spleen Sparing normal tissue is a prerequisite for a candidate cellular vehicle for cancer gene therapy. We therefore assesssed the distribution and fate of BOECs injected into the tail vein of tumor-free mice. To this end, BOECs were loaded with 111 In-DTPA labeled Ac-LDL, an approach similiar to 111 In oxine loading described previously. 49 The label was stably retained in the BOECs without leakage into the culture medium during the observation period of 48 h and neither morphology nor proliferation was influenced by the radioactive label (data not shown). Except for the liver, where cell-free 111 In-DTPA Ac-LDL is metabolized, 50 and the kidneys, which excrete
111
In-DTPA fragments, radioactive label recovered in organs following injection of 111 In-DTPA Ac-LDL loaded BOECs represents homed BOECs.
Sequestration of BOECs occurred in the lung and the spleen (Figure 2a) . No BOECs were detected in heart, gut, brain and blood, and only few in the bone marrow. The radioactivity observed in the liver and bladder most likely represents intermediates of 111 In-DTPA Ac-LDL metabolism and excreted 111 In-DTPA fragments, respectively. Organ-bound radioactivity rapidly decreased far beyond the degree attributable to radioactive decay, consistent with rapid destruction of the sequestered BOECs and subsequent excretion of the cell-free label.
We also determined sequestration of BOECs by immunohistochemistry. Few BOECs were detected in the lung (Figure 2b ) and spleen, while none were found in liver, kidneys and brain.
In summary, sequestration of human BOECs injected into the tail vein of non-irradiated mice is confined to the lung and spleen, where it occurs at low degree and is transient.
PlGF and VEGF increase migration and invasiveness of BOECs
The molecular mechanisms attracting EPCs or BOECs to tumors are unknown. As VEGF and, less so, PlGF have been suggested to guide recruitment of endogenous bone marrow-derived EPCs to tumors, we investigated the response of BOECs to these growth factors. Indeed, BOECs were attracted in a dose-dependent fashion by PlGF (Figure 3a ) and migrated along a VEGF gradient À/À cgc À/À mice. After metastases had formed, the mice received either no irradiation (a-c) or 6 Gy of total body g-irradiation (d-e). The next day, DiI-labeled BOECs were injected into the tail vein, this was repeated 2 days later. As a control, the same sequence was employed with DiI-labeled fibroblasts. (a, b) Tail vein injected BOECs home to lung but not to liver metastases. DiI-labeled BOECs were injected i.v. twice spaced 2 days apart, organs were procured 4 days later, cryosectioned and counterstained with Hoechst 33258 (blue). Numerous BOECs (red) are seen around and within a lung metastasis (a) while only very few BOECs are associated with a liver metastasis (b). Scale bars equal 200 mm. (c) Fibroblasts are sequestered in the lung but do not home to metastases. At 2 days after the last fibroblast injection lungs were procured, cryosectioned and stained with Hoechst 33258 (blue). Fibroblasts (red) are seen in the lung but not in the metastasis. Scale bar equals 100 mm. (d) Most lung metastases are targeted by tail vein injected BOECs. Homing efficacy of i.v. injected BOECs to established lung metastases was analyzed in five irradiated mice. The presence of less than five BOECs in a metastasis was considered as lack of homing and graded 'À'. The presence of at least five BOECs was defined to constitute homing and graded as moderate ('+'), marked ('++', as seen in e and f) and strong ('+++', as seen in a). Shown are the percentages of metastases (n ¼ 97) with homing of a given grade. (e, f) Some BOECs colocalize with tumor vessels, while the majority of BOECs are found extravascularly. Cryosections were stained with isolectin B 4 -FITC to decorate tumor vessels (green). Nuclei were stained with Hoechst 33258 (blue). The majority of BOECs (red) were found within the tumor proper while few BOECs (indicated by arrows) colocalized with tumor vessels. (f) Is a higher magnification of the rectangle in (e). Scale bars equal 200 mm (e) and 50 mm (f).
BOEC cancer gene therapy J Wei et al ( Figure 3b ). Interestingly, very high concentrations of VEGF did not increase migration. BOECs have to invade the tumor mass, if they are to exert a cytotoxic effect on tumor cells in addition to tumor endothelial cells. We therefore investigated invasion of BOECs using spheroids of LLC cells, which are known to express VEGF 38 and of LLC cells forced to express PlGF. In Figure 3c (upper panel) the space occupied by a single spheroid is surrounded by DiIlabeled BOECs that were added to the medium 1 h prior. At 48 h the BOECs have migrated to the spheroid with some of the BOECs invading it (visible as a ring-like structure; Figure 3c , lower panel). Invasion was much more pronounced in LLC cells overexpressing PlGF. Next we determined, whether a chimeric protein of VEGFR1 and IgG 1 Fc blocks invasion of BOECs into spheroids of LLC cells overexpressing PlGF. In medium controls and in the presence of IgG 1 Fc, BOECs migrated to and invaded the spheroid (Figure 3d , left and middle panels, respectively). In contrast, VEGFR1/IgG 1 Fc chimeric protein attenuated invasion (Figure 3d , right panels).
As VEGFR1 of the chimeric protein binds to PlGF and VEGF, this shows that PlGF and, possibly, VEGF enhance invasion of BOECs.
BOECs armed with yeast cytosine deaminase exert a strong bystander effect on LLC cells in vitro
We opted for a suicide gene to arm the BOECs, since this allows to delay cytotoxicity until the BOECs have incorporated into the tumor. We chose yeast cytosine deaminase fused to uracil phosphoribosyl transferase, because this fusion gene (FCU1) efficiently converts the non-toxic prodrug 5-fluorocytosin (5-FC) to 5-fluorouracil (5-FU), 51 which exerts a strong bystander effect. To address, whether BOECs exert a paracrine effect, supernatant of BOECs was added to LLC target cells. Indeed, the target cells responded with a significant increase in cell proliferation, which was not seen when supernatant from LLC cells was used (Figure 6d ).
To evaluate the bystander effect of BOEC/FCU1 cells on LLC tumors in vivo, mixtures of 25% BOEC/ FCU1 and 75% LLC cells were implanted subcutanously into Rag2 À/À cgc À/À mice and 5-FC was administered once tumors were palpable. Tumor growth was significantly retarded initially (Figure 6e ). However, tumor growth resumed. The transient nature of tumor growth inhibition suggests that the combined effects of low proliferation, short duration of the bystander effect and the presence of a paracrine effect compromise the ability of BOEC/FCU1 cells to control tumor growth.
Discussion
Targeting of experimental cancers by EPCs is just beginning to emerge. PBMCs are a ubiquitous source of EPCs. Unlike early outgrowth EPCs, late outgrowth BOECs have a large replicative capacity and are easy to modify, thus making them good candidates for cellular cancer gene therapy. In contrast to their strong bystander effect in vitro and their initial inhibitory effect on admixed tumor cells in vivo, armed BOECs were not effective when administered systemically in the presence of disseminated metastases. We have delineated important determinants of the efficacy of late BOECs for systemic gene therapy of disseminated experimental cancer.
Phenotype of BOECs and progenitor status
Analysis of BOECs derived from a large number of donors showed the cells to be CD34 + CD133 À c-kit
This confirmed the mature endothelial phenotype of BOECs. Of note, the BOECs did neither express CD133 nor c-kit and expression of CD34 showed marked interdonor variation. Thus, BOECs lack or variably express markers associated with progenitors. Conversely, their large proliferative capacity characterizes them as progenitor cells. It remains to be BOEC cancer gene therapy J Wei et al determined, whether the lack of progenitor status, as defined by lack of surface markers, contributes to the limited capability of BOECs to participate in the formation of new tumor vessels.
Regional homing of BOECs
Homing is an important determinant of the anti-tumor efficacy of BOECs. However, little is known about the homing mechanisms of BOECs. We utilized a multiorgan, multiple-metastases mouse model to compare the efficiency of EPC homing to various metastases within one organ and to metastases in different organs.
We show that metastases or tumors within a given organ specifically albeit differentially recruit i.v. injected BOECs. Homing presumably sufficient for a significant bystander effect occurred in just 35% of the lung metastases. While U87 gliomas avidly recruited i.v. injected BOECs, recruitment by LNT-229 and SF126 gliomas residing in the same brain area was modest compared to U87 gliomas. The causes of this differential recruitment of BOECs are yet to be uncovered. These may include competition of large numbers of metastases for a limited number of BOECs, differential secretion of PlGF, VEGF or other chemotactic stimuli, differences in the degree of vascularization and of hypoxia or divergence of vascular addresses. Irrespective of its cause, differential and therefore insufficient homing most likely presents a major reason why i.v. injected BOEC/FCU1 failed to prolong survival of metastasesbearing mice. Increasing dose and frequency of BOEC/ FCU1 administration and altering its timing may increase the efficacy of homing.
We further show that i.v. injected BOECs home to lung metastases but infrequently to metastases in the liver and kidneys. This contributed to the failure of i.v. injected BOEC/FCU1 cells to prolong the life of mice bearing metastases in these organs. A first pass effect in the lung of i.v. injected BOECs, organ-specific differences of tumor vessel architecture and vascular addresses (reviewed by Pasqualini et al.
53
) and of chemotactic factors most likely Lewis lung carcinoma cells were injected on day 0 into the tail vein of Rag2 À/À cgc À/À mice to generate the treatment group LLC-Irr-BOEC/ FCU1-5FC. On day 7, after metastases were established, mice received 3 Gy of total body g-irradiation (jagged arrow) followed by i.v. injection of 4 Â 10 5 BOEC/FCU1 cells (arrow head). After 2 days, mice received 6.25 mg 5-FC i.p. twice daily for 5 days (arrows). A second cycle of BOEC/FCU1 cells and 5-FC followed. The LLC-BOEC/FCU1-5FC treatment group was not irradiated. The control group LLC-Irr-BOEC/ FCU1-PBS had LLC metastases, received total body irradiation and BOEC/FCU1 cells, followed by i.p. PBS injections. Additional control groups bearing LLC metastases received irradiation and either 5-FC (LLC-Irr-5FC) or PBS (LLC-Irr-PBS). Tumor-free mice that received total body irradiation and BOEC/FCU1 cells followed by either 5-FC (Irr-BOEC/FCU1-5FC) or PBS injections (Irr-BOEC/FCU1-PBS, n ¼ 10) were used as toxicity controls. Unless stated otherwise, groups consisted of 12 mice. Survival data are depicted as Kaplan-Meier estimator analysis. Kruskal-Wallis and Mann-Whitney tests showed P40.05 for all comparisons. (b) Liver and kidney metastases, which are not well targeted by tail vein injected BOECs, contribute to mortality. Lung, liver and kidneys of mice from the same experiment described above were procured and inspected for visible metastases. Note massive metastases in liver and smaller metastases in the kidneys. Figure 1) BOECs to achieve homogenous populations may generate BOECs with preferential homing to tumors in specific organs.
Only few BOECs injected into the tail vein of tumorfree non-irradiated mice were transiently sequestered in lung and spleen. Importantly, BOECs were not sequestered significantly in the bone marrow, the liver or the kidneys. Thus, no side effects of armed BOECs should occur in these organs. Irradiation may increase sequestration into normal tissue. However, no side effects occurred in irradiated mice receiving 5-FC following systemic administration of BOEC/FCU1: neither survival, nor weight loss or appearance of the treated mice was different from control mice.
Molecular mechanisms of BOEC homing
BOECs administered into the blood stream have first to be attracted to the tumor. We have shown that BOECs migrate along a PlGF gradient and are attracted by tumor spheroids overexpressing PlGF. PlGF binds to VEGFR1, which is strongly expressed by BOECs. As many tumors overexpress PlGF, interaction of PlGF with VEGFR1 may be important for homing of BOECs in vivo. In addition, we have shown that BOECs, which strongly express VEGFR2, are attracted by VEGF in vitro. As many tumors overexpress VEGF, the VEGF/VEGFR2 axis may be a prominent mediator of BOEC homing in vivo. In contrast, BOECs do not express CXCR4 (our data and Rumpold et al.
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) and thus cannot respond to SDF-1, a potent attractor of hematopoietic stem cells. The role of hepatocyte growth factor/scatter factor, which is secreted by many tumors, in homing of BOECs warrants further study, since it has been implicated as a chemoattractant for endothelial progenitor cells. 55 Few BOECs were incorporated into tumor vessels when analyzed 2 days after BOEC injection. Longer follow-up is required to accurately assess the degree of definitive incorporation. Furthermore, since BOECs may not have an endogenous counterpart, this finding cannot be extrapolated to endogenous EPCs. Nevertheless, it is interesting to note that most bone marrow transplant studies 7, [9] [10] [11] 14, [19] [20] [21] [22] [23] 56 and studies that systemically infused endothelial precursors 2, 23, 25, 27 report a low degree of EPC incorportation. Thus, notwithstanding tumor type, tumor site and mouse strain-dependent variations of BOEC recruitment, 22 amplification of tumor cell death by obliteration of tumor vessels may not be prominent when using therapeutic BOECs. However, once resident in the tumor tissue proper, BOECs will impact on tumor cells via the bystander effect, similar to what has been described for therapeutic cells recruited from transplanted bone marrow. 7, 23 BOEC-FCU1 cells were generated by transduction and positive selection for 5 days. No change in morphology, proliferation and expression of VEGFR2, VE-cadherin or CD34 was noted after this short period of selection (data not shown). Thus, it is unlikely that transduction and selection impacted on homing and thus on therapeutic efficacy of the BOECs.
We employed myelosuppressive irradiation in our studies under the assumption, that it decreases competition of therapeutic BOECs with endogenous EPCs. This may have had an effect on homing yet to be characterized, since irradiation has been shown to increase angiogenesis by induction of VEGF, 57 eNOS, 58 MMP-9 59 and CXCL12 (SDF-1). 26 In addition, irradiation-induced tumor necrosis may mechanically trap BOECS. However, significant homing was also observed in the absence of irradiation. Furthermore, BOECs just trapped in an irradiated tumor may nevertheless contribute to its control.
The bystander effect of BOECs
BOECs are outpaced by the highly proliferative LLC cells leading to a substantial decrease in the ratio of BOECs to LLCs in vitro within a short period of time. We assume that this also took place in vivo, thus decreasing the bystander effect and contributing to the failure of BOEC/ FCU1 to control the disseminated LLC metastases. Human tumors grow slower than rodent tumors. Thus, an increased bystander effect can be expected when human tumors are targeted.
BOECs appear to be promising vehicles for tumorcytotoxic genes by virtue of their relative resistance to cell death. This resistance is demonstrated by the survival of a substantial minority of BOEC/FCU1 cells following administration of 5-FC, due to BOECs being less susceptible to 5-FU than tumor cells. Despite this resistance, the duration of maximal action by suicide genes on bystander cells is limited, as we have shown for FCU1. While generating longer-living BOECs, for example by transferring antiapoptotic genes, would increase the bystander effect, this would also increase the duration of the paracrine proliferative effect on tumor cells and the -remote -possibility of their malignant transformation. Thus, cytotoxic effectors other than suicide genes may constitute better therapeutic payloads for BOECs. A very intriguing possibility to increase the bystander effect while rendering payloadinduced cell death of BOECs irrelevant is to employ them as vehicles for replicating oncolytic viruses.
Conclusions
We have delineated important determinants of the efficacy of BOEC-mediated tumor gene therapy. First, tumors overexpressing PlGF or VEGF are candidate targets for BOECs. Second, the degree and homogeneity of homing leaves room for improvement. Third, cytotoxic effectors not affected by BOEC survival, proliferation arrest and paracrine tumor proliferative effect may constitute superior therapeutic payloads for BOECs. Addressing these determinants may allow for the improvement of BOECs to efficiently target tumors.
Materials and methods
Cell culture
BOECs were isolated and grown as previously described. 28 Briefly, human peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation with Biocoll separating solution (Biochrom, Berlin, Germany) from healthy volunteers. PBMCs were resuspended in ECBM2 (PromoCell, 
Migration assay
Modified Boyden chambers were used consisting of Transwell membrane filter inserts (Corning Costar Corp., Cambridge, MA, USA) with 8.0 mm pore size and coated with 10 mg/ml fibronectin (Sigma). BOECs (1 Â 10 5 ) in 100 ml ECBM2 containing 2% BSA (Serva, Heidelberg, Germany) were added to the upper inserts, which were set into wells containing 600 ml ECBM2/2% BSA and recombinant murine VEGF or recombinant human PlGF-2 (both from ReliaTech) in concentrations of 0, 0.1, 1, 10, 50 and 100 ng/ml. After 3 h the inserts were removed and fixed with 2% paraformaldehyde (PFA). The upper side of the membrane was scraped to remove cells. The transmigrated cells on the lower side of the transwell were stained by Hoechst 33258 and counted in five random high-power-fields using a fluorescence microscope (AX 70, Olympus, Hamburg, Germany).
Spheroid invasion assay
Ninety-six-well plates were coated with 1% agar (Sigma) in supplemented DMEM. 1 Â 10 3 LLC cells or LLC-PlGF cells were seeded in each well of a 96-well agar-coated plate in 100 ml supplemented DMEM for two days to form spheroids. These single spheroids were incubated for 18 h with 37 mg/ml recombinant human VEGFR1/ IgG 1 Fc chimera or 37 mg/ml human IgG 1 Fc (both from R&D Systems, Minneapolis, MN, USA) or supplemented DMEM. BOECs (2 Â 10 3 ) labeled with DiI (1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate; Molecular Probes) were added per well. Invasion of BOECs into the spheroids was documented at 1, 24 and 48 h. For some experiments tumor spheroids were picked out, fixed with 2% PFA, embedded in OCT compound (Sakura Finetek, Loeterwoude, The Netherlands) at À801C, cut into 5 mm thick sections and stained with Hoechst 33258. Invading DiI-labeled BOECs were analyzed by fluorescence microscopy (CK40, Olympus).
Gene transfer to BOECs
The retroviral construct pL(FCU1)IN was generated by inserting the cytosine deaminase/uracil phosphoribosyltransferase fusion gene (FCU1) into the pLXIN vector (BD Biosciences Clontech). The FCU1 cDNA was excised from the pCIneo-CD/UPRT plasmid (Transgene, Strasbourg, France) as a XhoI/SmaI fragment and cloned into the multiple cloning site of the pLXIN vector. The vectors pLXIN, pL(FCU1)IN and pLEIN (which contains the enhanced green fluorescent protein, EGFP) were stably transfected into GP2-293 packaging cells (BD Biosciences Clontech), using the calcium phosphate precipitation method. These cells were then transiently transfected with 7.5 mg of pVSV-G (BD Biosciences Clontech), employing the same transfection method. Virus-containing supernatants were harvested 48 h later, filtered through a 0.45 mm filter (Nalgene, Neerijse, Belgium) and used to transduce BOECs in the presence of 8 mg/ml Polybrene (Sigma). BOECs (5 Â 10 4 ) were seeded 24 h before transduction in supplemented ECBM2 culture medium without heparin into collagen-coated sixwell plates. Cells were exposed to virus-containing supernatants for 8 h, thereafter, medium was changed. After 48 h, BOECs transduced with the pLEIN vector were used to determine transduction efficiency by FACS analysis. Transduction efficiency routinely exceeded 95%. Cells were selected with 300 mg/ml G418 (Invitrogen, Karlsruhe, Germany) for 5 days. Thus, BOECs containing pLXIN (BOEC/Mock), pL(FCU1)IN (BOEC/FCU1) and pLEIN (BOEC/EGFP) were generated.
Determination of viable cells
Cells were counted using the CASY cell counter (Schärfe System, Reutlingen, Germany). Viability of cells was assessed by flow cytometry after incubation with 1 mg/ ml of propidium iodide. Cells not taking up propidium iodide were considered to be viable.
Bystander effect assay
BOECs transduced with pL(FCU1)IN were mixed with LLC cells to achieve proportions of transduced BOECs of 0, 1.6, 3.2, 6.3, 12.5, 25, 50, 75 and 100%. The mixtures were plated in triplicates in 24-well plates at a density of 3 Â 10 3 cells per well and allowed to attach overnight. In-DTP-Ac-LDL was isolated using size exclusion HPLC (purity 492%). BOECs were incubated with 111 In-DTPA-Ac-LDL for 4 h at 371C. Cells were washed and resuspended in culture medium containing 2% FBS. Radiolabeled cells (4 Â 10 5 , 111 In-Ac-LDL-BOECs) were injected into 8-to 10-week-old male Rag2 À/À cgc À/À mice via the tail vein. Mice were killed on day 2 (n ¼ 4) and on day 5 (n ¼ 3) after injection. Blood was aspirated by intracardiac puncture and femurs and solid organs were procured. All organs were weighted. Samples were analyzed using a g-counter and results expressed as counts per minute per mg tissue of each organ to correct for the different size of the organs. Samples obtained from noninjected mice served as background control. To further assess the biodistribution of BOECs to solid organs by immunofluorescence, 4 Â 10 5 DiI-labeled BOECs were tail vein injected into 8-to 10-week-old male Rag2
À/À cgc À/À mice. Solid organs were procured 2 days after BOEC injection and cryosections were analyzed for the presence of BOECs by staining for human vWF (1:25).
Assessment of homing to LLC metastases
LLC cells (5 Â 10 4 ) were injected into the tail vein of 8-to 12-week-old male Rag2 À/À cgc À/À mice. On day 7, when metastases were established, mice were subjected to 6 Gy of total body g-irradiation ( 137 Cs; Nordion, Gammacell 1000, Kanata, Canada) or left unirradiated. Starting 24 h later, mice received two tail vein injections of 4 Â 10 5 BOECs labeled with DiI (100 mg/ml) in 400 ml PBS spaced 2 days apart (n ¼ 5 per group). Human foreskin-derived fibroblasts cells (4 Â 10 5 ) injected in same numbers were used as controls (n ¼ 3). Mice were killed 2 days after the last injection. Organs were procured, fixed in 4% PFA, cryosectioned, stained with Hoechst 33258 and microscopically examined for DiI-fluorescence.
Assessment of homing to orthotopic U87 gliomas
Human U87, LNT-229 and SF126 glioma cells (5 Â 10 5 ) were stereotactically implanted unilaterally into the right striatum of 8-to 12-week-old male Rag2 À/À cgc À/À mice. After 4 days (SF126) or 14 days (U87 and LNT-229), when the gliomas were established, mice received 6 Gy of cranial g-irradiation. After 3 days, 1 Â 10 5 BOECs pulsed with BrdU at a concentration of 10 mM for 5 days were injected into the tail vein once (n ¼ 3). Control mice did not receive BOECs (n ¼ 3 for each glioma entity). After 1 day, the brains were procured, fixed in 4% PFA, cryosectioned and examined by immunohistochemistry for BrdU containing cells.
In vivo survival
For the treatment group LLC-Irr-BOEC/FCU1-5FC Lewis lung carcinoma cells were injected on day 0 into the tail vein of 8-to 10-week-old male Rag2 À/À cgc À/À mice. On day 7, after metastases were established, mice received 3 Gy of total body g-irradiation followed by i.v. injection of 4 Â 10 5 BOEC/FCU1 cells in 400 ml serumfree ECBM2 medium. After 2 days, mice received 6.25 mg 5-FC (Sigma) in 300 ml PBS i.p. twice daily for 5 days. A second cycle of BOEC/FCU1 cells followed by 5-FC was then given. A second group was treated as above except for radiation and was termed LLC-BOEC/ FCU1-5-FC. One control group -LLC-Irr-BOEC/FCU1-PBS -had LLC metastases, received total body irradiation and BOEC/FCU1 cells, followed by i.p. injections of 300 ml PBS. Additional control groups bearing LLC metastases received irradiation and either 5-FC (LLCIrr-5FC) or PBS (LLC-Irr-PBS) i.p. Tumor-free mice that received total body irradiation and BOEC/FCU1 cells followed by either 5-FC (Irr-BOEC/FCU1-5FC) or PBS i.p. injections (Irr-BOEC/FCU1-PBS, n ¼ 10) were used as toxicity controls. Unless stated otherwise, groups consisted of 12 mice. Tumor bearing mice were monitored daily and killed when appearing moribund as determined by a blinded observer. Mice that had received only BOEC/FCU1 cells were killed 3 months after the last inoculation of BOEC/FCU1 cells. Organs were removed and processed for histological analysis. All animal work was performed in accordance with state guidelines for animal care and use.
In vivo tumor inhibition LLC cells (1 Â 10 6 ) or a mixture of 1 Â 10 6 LLC cells with 3.5 Â 10 5 BOEC/FCU1 cells were resuspended in Matrigel (BD Biosciences; 1 mg/ml in DMEM) and inoculated s.c. into 8-to 10-week-old male Rag2 À/À cgc À/À mice. After 3 days, when tumors were palpable, mice (n ¼ 7 or 8 per group) received i.p. injections twice daily for 6 days of either 6.25 mg 5-FC in 300 ml PBS (LLC-BOEC/FCU1-5FC group and LLC-5FC group) or 300 ml PBS (LLC-BOEC/FCU1-PBS group and LLC-PBS group). Tumor size was determined every two days and tumor volume calculated using the formula volume ¼ width 2 Â length Â 0.4. The experiment was terminated when the first tumor started to bleed.
Immunohistochemistry and fluorescence microscopy
Organs were fixed with 4% PFA, cryoprotected in 20% sucrose/PBS, embedded in OCT compound at À801C and serially cut into 5 m thick sections. Slides were blocked with biotin/avidin blocking system (DAKO), 1% bovine serum albumin (Serva, Heidelberg, Germany) and 10% goat serum (DAKO). Slides were incubated at 41C with anti-human vWF (1:25 dilution in Tris-HCl buffer containing 0.1% Triton/0.1% BSA) followed by biotinylated goat anti-mouse secondary antibody (1:100; DAKO) and alkaline phosphatase-conjugated avidin/ biotin complexes (DAKO). Cells were visualized by the fast-red substrate system (DAKO) and counterstained with hematoxylin. To detect BrdU containing cells slides were microwaved in 0.01 M citric acid, pH 6.0 and then stained with anti-BrdU monoclonal antibody (Roche) according to the manufacturer's recommendation. To detect mature endothelial cells serially cut frozen 
